CTOR NASDAQ
Citius Oncology, Inc.
1W: -15.8%
1M: -11.8%
3M: -28.5%
YTD: -23.2%
1Y: -6.8%
$0.84
+0.01 (+1.31%)
Weekly Expected Move ±10.0%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$78.1M
52W Range0.491-6.19
Volume48,230
Avg Volume231,353
Beta3.58
Dividend—
Analyst Ratings
Company Info
CEOLeonard L. Mazur
Employees285
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2022-12-08
420 Lexington Avenue
New York City, NY 10170
US
New York City, NY 10170
US
347-627-0058
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Latest News
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Citius Oncology (NASDAQ:CTOR) Trading 9% Higher – What’s Next?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HOLUBIAK MYRON Z | A-Award | 850,000 | — | 2025-09-19 |
| HOLUBIAK MYRON Z | A-Award | 100,000 | — | 2025-09-19 |
| Smith Robert Joseph | A-Award | 300,000 | — | 2025-09-19 |
| Mazur Leonard L | A-Award | 1,700,000 | — | 2025-09-19 |
| Webb Carol | A-Award | 300,000 | — | 2025-09-19 |